Slides
Page 1
November 6, 2025 ››› Page 1 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Ben diagnosed 2024 Izzy diagnosed 2014 Company Overview NOVEMBER 6, 2025
Page 2
November 6, 2025 ››› Page 2 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Safe Harbor Certain statements in this presentation constitute forward-looking statements, including, without limitation, statements about: the perceived advantages of our products relative to competitive products and technologies; our anticipated growth and other measures of future operating results and financial performance; the development and commercialization of new products; our ability to secure and maintain necessary regulatory approvals and reimbursement for our existing products and new products under development. Our estimates and forward-looking statements are based on our management’s current assumptions and expectations of future events and trends, which affect or may affect our business, strategy, operations or financial performance. These statements are not guarantees of future performance and involve a number of risks and uncertainties, many of which are beyond our control, including the potential impacts of global macroeconomic conditions and our ability to successfully complete, manage and integrate acquisitions with our existing business. Our actual results may differ materially from those expressed or implied by such forward-looking statements. Some of the additional factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements can be found under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and in the other reports we file with the Securities and Exchange Commission. In addition, new risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. Estimates and forward-looking statements speak only as of the date they were made, and, except to the extent required by law, we undertake no obligation to update or review any estimate and forward-looking statement because of new information, future events or other factors. TRADEMARKS ©2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, Tandem Diabetes, Tandem, t:slim, Tandem Mobi, Mobi, Steadiset, Sigi, Tandem Source, t:slim G4, t:slim X2, Basal-IQ, Control-IQ, Control-IQ+, t:connect, positively different and our logos are trademarks, registered trademarks, and/or the subject of a pending trademark application in the U.S. and/or other territories worldwide. The trademarks Dexcom, G6 and G7 are registered trademarks of Dexcom, Inc. in the United States and/or other countries. FreeStyle, Libre and related brand marks are marks of Abbott Laboratories. All other trademarks are the property of their respective owners.
Page 3
November 6, 2025 ››› Page 3 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Large and underpenetrated worldwide market1 Robust portfolio offering choice and optionality o Two pump platforms: t:slim X2 and Tandem Mobi • Featuring Control-IQ+ Technology • Cleared for type 1 and type 2 diabetes • Multiple CGM sensor integrations o Tandem Source diabetes management platform Apx. 480,0002 in-warranty customers in25 countries Headquartered in San Diego with approximately 2,6002 employees worldwide Tandem Diabetes Care POSITIVELY DIFFERENT 1. Internal estimates factoring some data from the International Diabetes Federation and Centers for Disease Control and Prevent ion (CDC). 2. As of December 31, 2024. November 6, 2025 ››› Page 3 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved
Page 4
November 6, 2025 ››› Page 4 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Commercial Products
Page 5
November 6, 2025 ››› Page 5 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Control-IQ+ Technology CGM Integration(s)‡ Software Updates* Wireless Data Uploads† + Pump Portfolio Provides Choice in AID Systems *Future updates for all or some Tandem products may not be developed and may not be offered everywhere and would be subject t o applicable regulatory approvals. Software updates are only available to customers who are in warranty at the time they update their pump. Additional training may be required to access certain software updates. Charges may apply. Tandem may discontinue select software and features over time at its discretion. †Wireless uploads require a compatible phone and an internet or wireless data connection. Uploads to the Tandem Source platform do not take place in real time and should not be relied upon by healthcare providers, pump users, or caregivers for remote patient monitoring. Standard carrier data rates may apply. ‡ CGM sold separately. 1. As of November, 2025. Data on file, Tandem Diabetes Care. & t:slim X2 Insulin Pump All-in-one system, color touchscreen, multi-CGM integration 300-unit cartridge Tandem Mobi System World's smallest, durable automated insulin delivery system1 200-unit cartridge
Page 6
November 6, 2025 ››› Page 6 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Integrated with Industry-Leading CGMs1 t:slim X2 Pump Tandem Mobi2 Powered by Control-IQ + technology Dexcom G6 & G7 Abbott FreeStyle Libre 2 & 3 Plus 3 1. CGM sold separately. 2. Tandem Mobi only available to pump users who reside in the United States. 3. Global rollout began on t:slim X2 began October 2025. Integration not yet available for Tandem Mobi
Page 7
November 6, 2025 ››› Page 7 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Control–IQ+ Technology 1. As of November, 2025. Data on file, Tandem Diabetes Care. 2. Beck RW, et al. Diabetes Technol Ther. 2023;25(5):329-342. 115+ peer-reviewed manuscripts 440,000+ pump users worldwide 300,000,000+ patient days of Control-IQ technology use data1 ADA Standards of Care in Diabetes now includes AID Best-in-class outcomes with significantly fewer adverse events Immediate and sustained improvements across patient populations2 AutoBolus helps reduce user burden and prevent hyperglycemia Benefits featured four times in The New England Journal of Medicine Cleared for type 1 and type 2 diabetes, expanded weight and age indications, Unique, optional features to quickly adjust for lifestyle and fluctuating insulin needs TESTED TRUSTED BETTER AUTOMATED INSULIN DELIVERY (AID) PREDICTS AND HELPS PREVENT HIGHS AND LOWS
Page 8
November 6, 2025 ››› Page 8 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved TandemSource Data Management Reporting Decision Support* Customer Experience Supplies Ordering Software Update Device Management Account Management Customer Support Patient Engagement Reporting Patient Monitoring Decision Support Software Updates Clinic & Patient Support andDevice Management PATIENTS & CAREGIVERS CLINICIANS ADMINS Data Upload *Feature under development, not available at launch. THE GO-TO DIABETES MANAGEMENT PLATFORM
Page 9
November 6, 2025 ››› Page 9 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Goals & Growth Drivers
Page 10
November 6, 2025 ››› Page 10 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Serving a Large Underpenetrated Market People living with type 1 diabetes in the U.S. and 25 countries • Less than 40% of the~2M people living with type 1 diabetes in the U.S. use an insulinpump 1 • Less than 20% of the ~3M people living with type 1 diabetes in thecountries we serve use a pump 1 People living with type 2 diabetes • Approximately 5% of the greater than 2M people living with type 2 Insulin Intensive Diabetes in the U.S. use an insulin pump 1 1. Internal estimates factoring some data from the International Diabetes Federation and Centers for Disease Control and Prevent ion (CDC). Diabetes Type 1 Type 2 Cause Autoimmune: Body does not create insulin hormone Lifestyle/Genetics: Insulin resistance where cells do not use insulin properly Onset Sudden: typically before age 40 Progressive: Typically appears later in life Prevention None Diet and exercise Therapy Insulin Oral medication, injectables, insulin
Page 11
November 6, 2025 ››› Page 11 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved $- $200,000 $400,000 $600,000 $800,000 $1,000,000 $1,200,000 Domestic International A Return to Sales Growth STRONG RENEWALS & ASP EXPANSION 2013 2025* t:slim X2 t:slim X2 wG5 t:slim X2 Basal- IQ t:slim X2 Control- IQ t:slim X2 Mobile Bolus t:slim G4t:slim SALES Tandem Mobi *Chart includes estimated 2025 GAAP Sales guidance of $1B. 2023 and 2024 non -GAAP results exclude Tandem Choice Program to refle ct sales trend indicative of business performance. A reconciliation of 2023 and 2024 non -GAAP financial measures to their most directly comparable GAAP financial measures and addi tional information can be found in the Company's press release dated February 26, 2025 titled "Tandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance" in Table D “Reconciliation of GAAP versus Non -GAAP Financial Results” available at https://www.tandemdiabete s.com./ "
Page 12
November 6, 2025 ››› Page 12 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Significant Growth Drivers Scaling launch of Tandem Mobi Worldwide integration with Abbott Freestyle Libre 3 Plus and Dexcom G7 Expanded U.S. sales force 2025 preparations for direct sales in select EU countries beginning in 2026 Increasing U.S. pharmacy channel access Type 2 diabetes doubles U.S. served available market
Page 13
November 6, 2025 ››› Page 13 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Robust Pipeline
Page 14
November 6, 2025 ››› Page 14 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Innovative Pipeline Note: Products are under development and subject to future regulatory submission and clearance. FreeStyle Libre 3 Plus sensor integration Tubeless infusion set for Tandem Mobi Next Generation Mobi featuring Sigi tubeless technology SteadiSet extended wear infusion set Fully closed-loop AID New insulins GLOBAL LAUNCH INITIATED Android for Tandem Mobi Dual glucose-ketone sensor integration
Page 15
November 6, 2025 ››› Page 15 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved In Pursuit of . . . Fully Closed Loop Greater Ease of Use Leading clinical outcomes Automated settings At-a-glance management Optional meal announcements Note: Next-generation closed loop technology and future features are under development and subject to future regulatory submission and clearance.2012 Insulin Pump 2025 Expanded Indications (Ages 2+, T2D) 2015 Sensor-Augmented Insulin Pump 2018 Predictive Low Glucose Suspend 2020 Advanced Hybrid Closed Loop Continuous AID Improvement GROWING THE MARKET BY REDUCING DIABETES BURDEN
Page 16
November 6, 2025 ››› Page 16 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Summary & Financials
Page 17
November 6, 2025 ››› Page 17 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Historical DME Pricing Overview Reimbursement differs by customer insurance plan, channel, geography, and product Total amount realized per patient is approximately $7-8K in a four-year reimbursement cycle Domestic OUS % Distributor 60% 95% Pump 1 reimbursed every 4 years $4K $3K Supplies 120 cartridges and infusion sets used per patient per year $4K $4K Dollars and percentages are approximate
Page 18
November 6, 2025 ››› Page 18 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Delivering on our Strategy Differentiated Portfolio Robust insulin delivery ecosystem offers customer choice High customer satisfaction drives strong retention t:slim X2 – flagship pump Tandem Mobi – tiny and discrete Tandem Source data application available in the U.S. and scaling OUS Abbott’s Freestyle Libre 3 Plus integration U.S Innovative Pipeline Tandem Mobi – Android App Tandem Mobi now CE Marked- regulatory and reimbursement efforts underway Extended wear infusion technology Tandem Mobi – Tubeless feature Next generation Mobi – Miniaturized, durable, ergonomic patch Fully closed loop technology Incremental Revenue Opportunities Expanded and optimized U.S. Sales force Successfully executing multi- channel strategy with increasing pharmacy access Growing pump renewals opportunity Type 2 clearance doubles addressable market Direct sales in select European countries beginning 2026 Improving Gross Profits and Cash Flow ASP expansion Reduce component costs Reduce warranty costs Drive leverage in customer care by utilizing technology Manage scale of operating expenses LONG TERM FINANCIAL TARGETS OF 65% GROSS MARGIN AND 25% OPERATING MARGIN
Page 19
November 6, 2025 ››› Page 19 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Large and underpenetrated worldwide market1 Robust portfolio offering choice and optionality o Two pump platforms: t:slim X2 and Tandem Mobi • Featuring Control-IQ+ Technology • Cleared for type 1 and type 2 diabetes • Multiple CGM sensor integrations o Tandem Source diabetes management platform Apx. 480,0002 in-warranty customers in25 countries Headquartered in San Diego with approximately 2,6002 employees worldwide Tandem Diabetes Care POSITIVELY DIFFERENT 1. Internal estimates factoring some data from the International Diabetes Federation and Centers for Disease Control and Prevent ion (CDC). 2. As of December 31, 2024. November 6, 2025 ››› Page 19 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved
Page 20
November 6, 2025 ››› Page 20 © 2025 Tandem Diabetes Care, Inc. All Rights Reserved Tandem Diabetes Care Investor Relations: 858-366-6900 IR@tandemdiabetes.com